Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockACTH(4–10) Adamantyl Analog
Third-Party TestedPurity Standards
Total
$64.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic peptide (ACTH fragment analog, 9 residues)
Molecular formula
C50H69N11O11S
Molecular weight
1032.23 g/mol
Amino acids
9
Sequence
Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-NH₂
Modification
N-terminal acetylation; C-terminal amidation; C-terminal adamantylglycine residue (adamantane cage moiety).
Mechanism & Target Class
Mechanism & Target Class
A synthetic peptide corresponding to the ACTH(4–10) fragment scaffold, sharing the core Met-Glu-His-Phe-Pro-Gly-Pro sequence of Semax and extending it with Ala-Gly at the C-terminus. The terminal residue carries an adamantyl moiety — a rigid lipophilic cage incorporated in related peptide analogs to investigate how hydrophobic substitutions affect membrane penetration and proteolytic stability. N-terminal acetylation and C-terminal amidation cap the sequence, structural modifications studied for their effect on conformational stability and resistance to enzymatic degradation in tissue-preparation assays.
Storage & Handling
Storage & Handling
Lyophilized
Store refrigerated or at −20 °C, protected from light
use desiccant as needed.
Avoid repeated freeze-thaw cycles; protect from light and microbial contamination; prepare fresh aliquots for each experiment.
References
References
Reviews
- 1
Markov DD, Dolotov OV, Grivennikov IA (2023). Int. J. Mol. Sci.
Primary research
- 2
Radchenko AI, Sobolevsky OI, et al. (2025). Acta Naturae
Primary research
- 3
Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F (2022). ACS Chem. Neurosci.
- 4
Sudarkina OY, Remizova JA, et al. (2021). Int. J. Mol. Sci.
- 5
Dolotov OV, Karpenko EA, Seredenina TS, et al. (2006). J. Neurochem.
- 6
Medvedeva EM, Dergunova LV, Filippenkov IB, et al. (2014). BMC Genomics
- 7
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006). Brain Res.
- 8
Shadrina MI, Dolotov OV, Grivennikov IA, et al. (2001). Neurosci. Lett.
- 9
Agapova TY, Agniullin YV, Shadrina MI, et al. (2007). Neurosci. Lett.
- 10
Shadrina M, Kolomin T, Agapova T, et al. (2009). J. Mol. Neurosci.
- 11
Storozhevykh TP, Tukhbatova GR, Senilova YE, et al. (2007). Bull. Exp. Biol. Med.
- 12
Grivennikov IA, Dolotov OV, Zolotarev YA, et al. (2008). Restor. Neurol. Neurosci.
- 13
Eremin KO, Kudrin VS, Saransaari P, et al. (2005). Neurochem. Res.
- 14
Bashkatova VG, Koshelev VB, Fadyukova OE, et al. (2001). Brain Res.
- 15
Dmitrieva VG, Kolomin TA, Shadrina MI, et al. (2009). Cell Mol. Neurobiol.
- 16
Medvedeva EV, Dmitrieva VG, Limborska SA, et al. (2017). Mol. Genet. Genomics
- 17
Filippenkov IB, Stavchansky VV, Denisova AE, et al. (2020). Genes
- 18
Dergunova LV, Filippenkov IB, Stavchansky VV, et al. (2021). Mol. Biol.
- 19
Stavchansky VV, Yuzhakov VV, Sevan'kaeva LE, et al. (2024). Curr. Issues Mol. Biol.
- 20
Filippenkov IB, Shpetko YY, Stavchansky VV, et al. (2024). Biomedicines
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
